Officials at the U.S. Department of Health and Human Services, led by Secretary Robert F. Kennedy Jr., privately discussed restricting, and according to some reports even banning, commonly used selective serotonin reuptake inhibitors, the antidepressant class that includes Zoloft, Prozac and Lexapro. Kennedy this week unveiled a MAHA action plan that pairs new payment and training incentives with guidance to help patients taper medications when clinically appropriate.
Reports That Officials 'Explored' SSRI Restrictions
As reported by Honolulu Star-Advertiser, two people familiar with internal talks told reporters that HHS officials explored banning or restricting certain drugs in the SSRI class. That reporting, which cited Reuters, surfaced as the department rolled out broader efforts to tackle what Kennedy calls the "overmedicalization" of mental health.
What HHS Announced At The MAHA Summit
HHS says the new initiative is aimed at "deprescribing" when it is clinically indicated, not at ordering mass stoppages of antidepressants. According to HHS, the MAHA action plan includes new Medicare and Medicaid reimbursement pathways for clinicians who support tapering, federal training modules focused on deprescribing and plans to analyze prescribing data. Kennedy framed the shift as moving away from treating psychiatric medications "as the default" and toward more shared decision-making between patients and clinicians.
Reaction From Psychiatrists And Advocates
Professional organizations have welcomed the focus on mental health while warning that the rhetoric risks flattening a complicated set of problems. The American Psychiatric Association, in comments reported by The Guardian, said the real issues include access, workforce shortages and uneven quality of care, and argued that "deprescribing alone is not a sufficient response."
Why This Matters For Patients
Use of SSRIs is widespread: The Independent reports that roughly 17 percent of American adults take these drugs, so any new constraints could affect millions of people. Clinicians caution that suddenly stopping antidepressants can trigger discontinuation symptoms such as dizziness, insomnia and flu-like feelings and that tapering has to be tailored to each patient, according to Pharmacy Times. Many patients and clinicians say the medications are life-saving for some, which is why safeguards and clear clinical guidance sit at the center of the current debate.
HHS Pushback On 'Ban' Reports
HHS has pushed back on any suggestion that it is preparing to outlaw SSRIs. In a statement to Honolulu Star-Advertiser, HHS spokesman Andrew Nixon said the department "has not had any discussions about banning SSRIs" and called claims to the contrary false.
What To Watch Next
The department says it will convene experts, host webinars for prescribers and develop clinical guidance in the coming weeks as it pilots payment pathways for tapering support. According to HHS, SAMHSA will run training modules and an expert panel will help craft clinical recommendations. Implementation details, including the exact language of guidance, how insurers handle coverage and what safety checks are built in, will determine whether the MAHA push actually changes prescribing patterns on the ground.
Patients should not stop medications without talking to their clinicians, and psychiatrists stress that any deprescribing must preserve access to therapy and close clinical supervision. The next several weeks of guidance and data-sharing will reveal whether the department’s move can curb overprescribing while avoiding harm to people who rely on these drugs.
.jpg){kind=link}